Abbott Laboratories (NYSE: ABT) is a global healthcare company known for its diverse portfolio, including medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. The company competes with other healthcare giants like Johnson & Johnson and Medtronic. On July 18, 2025, Citigroup maintained its "Buy" rating for Abbott Labs, with the stock trading at around $124.50. The action associated with this rating is "hold," as highlighted by StreetInsider.
Abbott's strong buy recommendation for the second quarter of 2025 is supported by several factors. The company's robust management and diverse portfolio play a significant role in its positive outlook. Abbott's healthy cash flow and strategic capital return further enhance investor confidence. The promising pipeline of new products also contributes to the company's growth potential.
The current stock price of ABT is $124.17, showing an increase of approximately 3.04% or $3.66. This reflects investor optimism and confidence in the company's future prospects. Today, the stock has traded between a low of $122.27 and a high of $125.63, indicating some volatility but overall positive movement.
Over the past year, ABT has experienced a high of $141.23 and a low of $99.71. This range demonstrates the stock's potential for growth and the challenges it has faced. Despite these fluctuations, Abbott's market capitalization remains strong at approximately $216.04 billion, showcasing its stability and market presence.
The trading volume for ABT on the NYSE is 10.76 million shares, indicating active investor interest. This level of trading activity suggests that investors are closely monitoring Abbott's performance and are optimistic about its future. The combination of a strong buy recommendation, robust management, and a promising pipeline makes Abbott Laboratories an attractive investment opportunity.
